Bar Pipa
We pay for a post of 10$
DocMorris AG

DocMorris AG

0RRB.L LSE

$10.35
-4.38%

Key Statistics

Market Cap
$497.91 M
Volume
6,162
Open
$10.67
Day Range
10.25 - 10.67
52W Range
10.25 - 101.25
Price AVG 50
$80.94

About DocMorris AG

Founded in 1993 and headquartered in Frauenfeld, Switzerland, DocMorris AG primarily manages digital pharmacies alongside a wholesale division specializing in pharmaceuticals and health-related merchandise, operating within Switzerland and across international markets. Its product portfolio encompasses both prescription-required and over-the-counter medications, and also includes consumer health products, beauty and personal care items, nutritional supplements, pain relievers, and first aid provisions. Furthermore, it offers medicine management services. Complementing its online activities, the company also runs physical pharmacy outlets. Sales are conducted directly to medical practitioners, through other online mail-order pharmacies, and to private individuals, under brands such as Zur Rose, PromoFarma, TeleClinic, and DocMorris. Known as Zur Rose Group AG until May 2023, the company subsequently rebranded as DocMorris AG.

Asset Type: Common Stock
Sector: Healthcare
Industry: Medical - Distribution

Discussion

Authentication Required

You must be logged in to post a comment.

DocMorris on the Rise: How Online Pharmacies Are Conquering Germany

DocMorris on the Rise: How Online Pharmacies Are Conquering Germany

Introduction: Growth That Surprised the Market

Wednesday was a triumphant day for the Swiss online pharmacy and telemedicine group DocMorris 0RRB.L ... . The company’s shares jumped by approximately 7 percent after it published second-quarter results that exceeded expectations. External revenue increased by 15.2 percent in local currency, reaching CHFUSD ... CHF 309.7 million. Reported revenue rose by 16.1 percent to CHF 295.4 million.

What is behind this success? The main driver was Germany, where external revenue from prescription medicines surged by 45.8 percent. Digital services, including TeleClinic and the marketplace business, grew by 80 percent. The active customer base expanded by 1.1 million people, reaching 12.9 million.

In this article, we will examine the key factors driving DocMorris’s growth, assess its prospects, and consider whether the company will be able to reach EBITDA break-even in 2026.

Key Financial Indicators

Revenue Growth of 15.2 Percent

DocMorris’s external revenue increased by 15.2 percent in local currency to CHF 309.7 million. Reported revenue rose by 16.1 percent to CHF 295.4 million. This significant increase exceeded market expectations.

Growth was primarily driven by Germany, where external revenue from prescription medicines surged by 45.8 percent. This represented an acceleration compared with the first quarter, when growth stood at 28.6 percent.

Digital Services Grow by 80 Percent

Digital services, including TeleClinic, retail media, and the marketplace business, grew by 80 percent to CHF 13.9 million. This segment is becoming increasingly important for the company, helping to diversify its sources of revenue.

The expansion of digital services indicates that DocMorris is successfully developing an ecosystem that extends beyond the traditional online pharmacy business.

The Active Customer Base Continues to Grow

DocMorris’s active customer base increased by 1.1 million compared with the previous year, reaching 12.9 million. This growth was supported by a significant influx of new customers purchasing...

Continue reading...
0
0
Navigation menu
instaforex banner